CN113677339A - Iap抑制剂与免疫检查点抑制剂的组合 - Google Patents
Iap抑制剂与免疫检查点抑制剂的组合 Download PDFInfo
- Publication number
- CN113677339A CN113677339A CN202080018049.3A CN202080018049A CN113677339A CN 113677339 A CN113677339 A CN 113677339A CN 202080018049 A CN202080018049 A CN 202080018049A CN 113677339 A CN113677339 A CN 113677339A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- compounds
- lcms
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
Abstract
涉及一类用作IAP抑制剂的式(I)所示化合物、其异构体或其药学上可接受的盐与免疫检查点抑制剂的组合,以及该组合在制备治疗癌症药物中的用途。
Description
PCT国内申请,说明书已公开。
Claims (23)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019101728678 | 2019-03-07 | ||
CN201910172867 | 2019-03-07 | ||
PCT/CN2020/078234 WO2020177765A1 (zh) | 2019-03-07 | 2020-03-06 | Iap抑制剂与免疫检查点抑制剂的组合 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113677339A true CN113677339A (zh) | 2021-11-19 |
CN113677339B CN113677339B (zh) | 2023-08-01 |
Family
ID=72338383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080018049.3A Active CN113677339B (zh) | 2019-03-07 | 2020-03-06 | Iap抑制剂与免疫检查点抑制剂的组合 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220175917A1 (zh) |
EP (1) | EP3936126A4 (zh) |
CN (1) | CN113677339B (zh) |
AU (1) | AU2020233068A1 (zh) |
CA (1) | CA3132740A1 (zh) |
WO (1) | WO2020177765A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101595121A (zh) * | 2006-10-12 | 2009-12-02 | 诺瓦提斯公司 | 作为iap抑制剂的吡咯烷衍生物 |
CN101605786A (zh) * | 2006-12-19 | 2009-12-16 | 健泰科生物技术公司 | 细胞凋亡抑制剂的咪唑并吡啶抑制剂 |
CN101951766A (zh) * | 2008-01-24 | 2011-01-19 | 泰特拉洛吉克药业公司 | 凋亡抑制蛋白抑制剂 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100984459B1 (ko) * | 2004-07-02 | 2010-09-29 | 제넨테크, 인크. | Iap의 억제제 |
CA2574040C (en) * | 2004-07-15 | 2014-05-06 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
CA2944240A1 (en) * | 2014-04-04 | 2015-10-08 | Iomet Pharma Ltd | Indole derivatives as ido/tdo inhibitors |
PL3712162T3 (pl) * | 2017-11-13 | 2022-11-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | MIMETYKI SMAC STOSOWANE JAKO INHIBITORY lAP I ICH ZASTOSOWANIE |
JP2022511437A (ja) * | 2018-11-26 | 2022-01-31 | デバイオファーム インターナショナル エス.エー. | Hiv感染の組み合わせ治療 |
-
2020
- 2020-03-06 US US17/436,991 patent/US20220175917A1/en active Pending
- 2020-03-06 WO PCT/CN2020/078234 patent/WO2020177765A1/zh active Application Filing
- 2020-03-06 CN CN202080018049.3A patent/CN113677339B/zh active Active
- 2020-03-06 EP EP20766360.0A patent/EP3936126A4/en active Pending
- 2020-03-06 AU AU2020233068A patent/AU2020233068A1/en active Pending
- 2020-03-06 CA CA3132740A patent/CA3132740A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101595121A (zh) * | 2006-10-12 | 2009-12-02 | 诺瓦提斯公司 | 作为iap抑制剂的吡咯烷衍生物 |
CN101605786A (zh) * | 2006-12-19 | 2009-12-16 | 健泰科生物技术公司 | 细胞凋亡抑制剂的咪唑并吡啶抑制剂 |
CN101951766A (zh) * | 2008-01-24 | 2011-01-19 | 泰特拉洛吉克药业公司 | 凋亡抑制蛋白抑制剂 |
Non-Patent Citations (1)
Title |
---|
CONOR J KEARNEY ET AL: "PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF", 《CELL DEATH AND DIFFERENTIATION》 * |
Also Published As
Publication number | Publication date |
---|---|
EP3936126A4 (en) | 2022-12-21 |
CA3132740A1 (en) | 2020-09-10 |
EP3936126A1 (en) | 2022-01-12 |
WO2020177765A1 (zh) | 2020-09-10 |
CN113677339B (zh) | 2023-08-01 |
AU2020233068A1 (en) | 2021-09-23 |
US20220175917A1 (en) | 2022-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI797186B (zh) | 整合應激路徑之調節劑 | |
TWI747879B (zh) | 作為抗病毒劑之四環吡啶酮化合物 | |
TWI817929B (zh) | 趨化介素受體調節劑及其用途 | |
CN111051328B (zh) | 作为抗癌剂的环二核苷酸 | |
JP2021514982A (ja) | インドール−2−カルボニル化合物及びb型肝炎治療のためのそれらの使用 | |
EP3447052B1 (en) | Methods of preparing new idh1 inhibitors | |
CN111406063B (zh) | 作为抗癌剂的环二核苷酸 | |
CN102118969B (zh) | 组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂 | |
JP2021503458A (ja) | 新規のジヒドロイソキサゾール化合物及びb型肝炎治療のためのそれらの使用 | |
JP2021507906A (ja) | 抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物 | |
EA025794B1 (ru) | Противовирусные соединения | |
JP2022508786A (ja) | 環状ジヌクレオチド化合物及びその使用 | |
EP3024824A1 (en) | Therapeutically active compounds and use thereof | |
KR20200142508A (ko) | PI3K-γ 저해제로서의 아미노피라진 다이올 화합물 | |
US20240024488A1 (en) | Compounds and uses thereof | |
KR20230019507A (ko) | Il-17의 조절제로서의 이미다조피리다진 | |
JP2022517418A (ja) | アデノシンアンタゴニストとしてのヘテロ環式化合物 | |
CN111247161B (zh) | 用作iap抑制剂的smac模拟物及其用途 | |
CN112574278A (zh) | 作为蛋白降解剂杂环类化合物及其制备方法和医药应用 | |
CN113677339B (zh) | Iap抑制剂与免疫检查点抑制剂的组合 | |
CN111315750B (zh) | 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物 | |
WO2019074824A1 (en) | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE | |
EA040409B1 (ru) | Применяемые в качестве ингибиторов iap миметики smac и их применение | |
CN109563136A (zh) | 作为C5a受体拮抗剂的环肽 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |